National Immunotherapy Cancer Research Foundation Inc

Search Intent Cockpit

National Immunotherapy Cancer Research Foundation Inc Form 990, Revenue, CEO Pay, and IRS Filing Signals

National Immunotherapy Cancer Research Foundation Inc is surfaced here as a decision-ready nonprofit financial profile, not just a charity listing. The page consolidates IRS Form 990 revenue, expenses, assets, tax-exempt classification, executive compensation, mission score, red flags, and year-by-year filing history so donors, researchers, journalists, and grant teams can answer the common search questions around National Immunotherapy Cancer Research Foundation Inc in one place.

Is National Immunotherapy Cancer Research Foundation Inc Legit?

Significant Concerns

Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →

IRS 990 Data Cockpit

Where the Money Comes From and Where It Goes

Across stored filings, National Immunotherapy Cancer Research Foundation Inc shows contribution history pending. Next enrichment targets: revenue-source fields, IRS BMF classification.

Decision Cockpit

One-Stop Donor, Research, and Peer Context Hub

Donation Decision Flow

From Trust Check to Better Alternatives

Alternative Shopping

Similar Nonprofits Donors Should Compare

Browse the full Category H peer market in New Jersey →

Next Best Actions

Keep the Investigation Moving

National Immunotherapy Cancer Research Foundation Inc directs 15% of its spending to programs. This falls below the 65% benchmark. Donors may want to investigate further.

About National Immunotherapy Cancer Research Foundation Inc

National Immunotherapy Cancer Research Foundation Inc (EIN: 223067246) is a nonprofit organization based in Flemington, NJ, classified under NTEE code H30Z. The organization reported total revenue of $526K and total assets of $1.2M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of National Immunotherapy Cancer Research Foundation Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.

Organization Overview

National Immunotherapy Cancer Research Foundation Inc is a small nonprofit that has been operating for 36 years, with 14 years of IRS 990 filings on record (2010–2023). Revenue has grown at a compound annual rate of -3.2%.

Key Financial Metrics (2023)

From the most recent IRS 990 filing on record:

Financial Health Grade: A

In 2023, National Immunotherapy Cancer Research Foundation Inc reported a surplus of $53K with revenue exceeding expenses, holds 128.8 months of operating reserves (strong position), has a debt-to-asset ratio of 43.9% (moderate leverage).

Financial Trends

Over 14 years of filings (2010–2023), National Immunotherapy Cancer Research Foundation Inc's revenue has declined at a compound annual growth rate (CAGR) of -3.2%.

IRS Tax-Exempt Classification

Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.

AI Transparency Report

Mission Effectiveness Score

NonprofitSpending's AI analysis rates National Immunotherapy Cancer Research Foundation Inc with a Mission Score of 45 out of 100 (Fair). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.

Spending Breakdown

• admin: 50%
• programs: 15%
• fundraising: 35%

According to IRS 990 filings, National Immunotherapy Cancer Research Foundation Inc allocates its expenses as follows: admin: 50%, programs: 15%, fundraising: 35%. Only 15% is directed toward programs, which may warrant further investigation by donors.

Key Financial Metrics (2023)

From the most recent IRS 990 filing on record:

• The organization reported a surplus of $53K, with revenue exceeding expenses.
• Debt-to-asset ratio: 43.9%.

Executive Compensation Analysis

Executive compensation cannot be assessed as it is not disclosed in the provided data, which is a significant transparency concern for an organization with substantial assets.

Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.

Red Flags

The following concerns were identified during AI analysis of National Immunotherapy Cancer Research Foundation Inc's IRS 990 filings:

• In 2023, only $15,146 (approx. 10% of total expenses) was spent on programs, despite $1,051,896 in assets.
• Significant fluctuations in revenue, from $330,414 in 2019 to $4,423 in 2022, raise questions about funding stability and strategy.
• A high percentage of expenses consistently allocated to administrative and fundraising activities rather than direct program services.
• Lack of detailed information regarding executive compensation and specific program outcomes.

Strengths

The following positive indicators were identified for National Immunotherapy Cancer Research Foundation Inc:

• The organization maintains a healthy asset base, with $1,051,896 in 2023, indicating financial stability.
• Consistent filing of financial documents, demonstrating adherence to reporting requirements.

Frequently Asked Questions about National Immunotherapy Cancer Research Foundation Inc

Filing History

IRS 990 filing history for National Immunotherapy Cancer Research Foundation Inc showing financial trends over 14 years of public records:

Over 14 years of IRS 990 filings (2010–2023), National Immunotherapy Cancer Research Foundation Inc's revenue has declined by 34.5%, moving from $231K to $151K. Total assets increased by 79.1% over the same period, from $587K to $1.1M. Total functional expenses fell by 43.6%, from $174K to $98K. In its most recent filing year (2023), National Immunotherapy Cancer Research Foundation Inc reported a surplus of $53K, with revenue exceeding expenses. The organization holds $462K in liabilities against $1.1M in assets (debt-to-asset ratio: 43.9%), resulting in net assets of $590K.

Year-by-Year Financial Summary

• 2023: Revenue of $151K, expenses of $98K, and assets of $1.1M (revenue +3324.4% year-over-year).
• 2022: Revenue of $4K, expenses of $136K, and assets of $1.1M (revenue -26.3% year-over-year).
• 2021: Revenue of $6K, expenses of $78K, and assets of $1.4M (revenue -57.0% year-over-year).
• 2020: Revenue of $14K, expenses of $1.0M, and assets of $1.6M (revenue -95.8% year-over-year).
• 2019: Revenue of $330K, expenses of $33K, and assets of $1.7M (revenue +0.7% year-over-year).
• 2018: Revenue of $328K, expenses of $29K, and assets of $1.6M (revenue +9.4% year-over-year).
• 2017: Revenue of $300K, expenses of $253K, and assets of $1.4M (revenue +28.3% year-over-year).
• 2016: Revenue of $234K, expenses of $228K, and assets of $1.5M (revenue -18.5% year-over-year).
• 2015: Revenue of $287K, expenses of $576K, and assets of $1.5M (revenue -2.5% year-over-year).
• 2014: Revenue of $294K, expenses of $52K, and assets of $1.4M (revenue +0.1% year-over-year).
• 2013: Revenue of $294K, expenses of $127K, and assets of $1.2M (revenue +8.9% year-over-year).
• 2012: Revenue of $270K, expenses of $14K, and assets of $984K (revenue +23.7% year-over-year).
• 2011: Revenue of $218K, expenses of $10K, and assets of $778K (revenue -5.5% year-over-year).
• 2010: Revenue of $231K, expenses of $174K, and assets of $587K.

View Individual Filing Years

Explore detailed financial data from each IRS 990 filing year for National Immunotherapy Cancer Research Foundation Inc:

Data Sources and Methodology

This transparency report for National Immunotherapy Cancer Research Foundation Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.

IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.

Disclaimer

AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.